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INTRODUCTION
The human liver receives sympathetic input via the ce-
liac plexus and parasympathetic input mainly from the 
vagus nerve [1]. Hepatic nerve fibers are found around 
the hepatic arteriole, portal vein, bile duct in the portal 
tract, and central veins inside the hepatic lobule along 
the sinusoid [2]. The hepatic nerve is involved in hemo-
dynamics, bile flow regulation, as well as in carbohydrate 
and lipid metabolism [3,4]. Activation of the sympathetic 
nerves increases glucose and lactate release, bile flow, 
and bile acid secretion [5], and sympathetic nervous 
overactivity is related to the severity of cirrhosis [3]. 
The S100 protein is a low molecular weight (9 to 13 kDa) 
calcium (Ca2+)-binding protein of the helix-loop-helix 
type [6], which acts as a serum marker for brain dam-
age in cirrhosis with hepatic encephalopathy [7,8]. The 
nervous system-specific S100B isoform is a cytoplasmic 
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Background/Aims: Hepatic innervation in liver diseases is not fully understood. 
We here evaluated S100B expression as a marker of hepatic nerves in patients 
with various chronic liver diseases, topographically and semi-quantitatively.
Methods: Liver specimens were obtained from 70 subjects (three controls, and 32 
chronic hepatitis B, 14 chronic hepatitis C, 14 liver cirrhosis, and seven hepato-
cellular carcinoma patients). The hepatic nerve density was calculated based on 
immunohistochemical staining of S100B protein in the portal tracts and hepatic 
lobules. S100B mRNA levels were semi-quantitatively assessed as the S100B/glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA ratio. 
Results: The densities of the hepatic nerves in portal tracts of chronic liver 
diseases were not significantly different from those of normal controls but the 
hepatic nerve densities in lobular areas of liver cirrhosis were significantly de-
creased (p = 0.025). Compared to the control, the S100B/GAPDH mRNA ratio was 
significantly decreased in chronic liver diseases (p = 0.006) and most decreased 
in chronic hepatitis C patients (p = 0.023). In chronic liver diseases, The S100B/
GAPDH mRNA ratio tended to decrease as the fibrosis score > 0 (p = 0.453) but the 
overall correlation between the S100B/GAPDH mRNA ratio and fibrosis score was 
not statistically significant (r = 0.061, p = 0.657).
Conclusions: Hepatic innervation is decreased in cirrhotic regenerating nodules 
compared to the control group and seems to decrease in early stages of fibro-
sis progression. Further studies are needed to clarify the association between 
changes of hepatic innervation and chronic liver disease progression. 
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component of glial cells [9,10], and marks hepatic nerve 
fibers in the portal area [11]. 
In chronic liver disease, the distribution of intrahe-
patic nerve fibers is altered, accompanying structural 
changes in the hepatic lobules [2]; however, changes in 
hepatic innervation in chronic liver diseases has not yet 
been fully elucidated. We here aimed to evaluate the 
density of hepatic nerves in various chronic liver diseas-
es, topographically and semi-quantitatively.
METHODS
Tissue specimens
The study was approved by the Institutional Review 
Boards of Ewha Womans University Mokdong Hospi-
tal (EUMC 2015-03-026-001). All patients gave informed 
consent. We included samples from three normal con-
trols and 67 patients with chronic liver diseases (32 
chronic hepatitis B [CHB], 14 chronic hepatitis C [CHC], 
14 liver cirrhosis [LC], and seven hepatocellular carcino-
ma [HCC] patients). Normal liver tissues were obtained 
from two patients undergoing laparoscopic cholecystec-
tomy, one patient undergoing angiosarcoma lobectomy. 
Liver tissues were obtained by ultrasonography-guid-
ed needle biopsy or surgical wedge resection at Ewha 
Womans University Mokdong Hospital from May 2006 
to July 2008. Biopsy was done before anti-viral therapy 
started in patient with viral hepatitis. Chronic hepatitis 
was considered as CHB and CHC. The following were 
considered as chronic liver diseases: CHB, CHC, and LC. 
Fibrosis score was analyzed from 56 patients (28 CHB, 14 
CHC, and 14 LC). The necroinflammation score and fi-
brosis score were determined in terms of Knodell’s his-
tological activity index (HAI) [12]. 
S100B immunohistochemistry
Immunohistochemistry was performed using the LSAB 
System/HRP kit (DaKoCytomation, Carpinteria, CA, USA). 
Endogenous peroxidase activity was blocked by incuba-
tion in ready-to-use peroxidase blocking agent (DaKoCy-
tomation). Non-specific protein binding was blocked by 
incubating tissues with Protein Block Serum-free (DaKo-
Cytomation). Tissues were incubated with the polyclonal 
rabbit anti-S100B antibody (1:800 dilution; DaKoCyto-
mation, Copenhagen, Denmark). Subsequently, the tis-
sues were incubated for 15 minutes with biotinylated 
anti-rabbit immunoglobulins in phosphate-buffered 
saline, followed by incubation with streptavidin per-
oxidase for 15 minutes. 3, 3′-Diaminobenzidine tetra-
chloride (Liquid DAB Substrate Chromogen System, 
DaKoCytomation) was used as substrate for the color 
reaction and was counterstained with Mayer’s hematox-
ylin. The stained tissues were then photographed using 
an Olympus microscope equipped with a ColorView3 
digital camera (Soft Imaging System GmbH, Münster, 
Germany).
Hepatic nerve density
S100B-positive spindle-like nerve fibers were counted at 
the portal tracts and the hepatic lobules. The S100B-pos-
itive nerve fibers were counted at least 2 high-power 
fields per specimen. One to five specimens per patient 
were evaluated. The mean number of stained nerve fi-
bers per portal tract and hepatic lobule was calculated. 
In patients with LC, hepatic nerves were calculated at 
fibrous septae and regenerating nodules. The hepatic 
nerve density in the hepatic lobule was compared to that 
in the regenerating nodules in LC patients. In HCC pa-
tients, some S100B-stained fibers considered to be he-
patic nerve fibers were found in stroma and tumorous 
tissue. Because tumor stroma and tumor parenchyma 
could not be clearly distinguished in some specimens, 
we present hepatic nerve density of HCC in the table but 
Figure 1. Distribution of nerve fibers in immunohistochem-
ical stain. S100-positive nerve fibers are seen in the portal 
tract (arrows; liver cirrhosis patient, ×100).
271
Baik SJ, et al. Decreased S100B expression in CLD
www.kjim.orghttps://doi.org/10.3904/kjim.2015.296
excluded the density from statistical analysis. 
S100B mRNA reverse transcription polymerase 
chain reaction
For mRNA preparation, the tissues were incubated in 
easy-BLUE (800 mL; European Biotech Network, Dolem-
breux, Belgium) for 5 minutes at room temperature. Af-
ter adding 200 μL chloroform, the tissues were vortexed. 
The tissues were centrifuged at 12,000 rpm for 15 min-
utes at 4°C. To the supernatant, 400 mL isopropyl al-
cohol was added and mixed by inverting two or three 
times. The mixture was incubated for 5 minutes at room 
temperature, and centrifuged at 12,000 rpm for 10 min-
utes at 4°C. After centrifugation, the precipitated RNA 
was washed with ethanol, dried, and resuspended in 25 
mL of diethylpyrocarbonate-treated distilled water be-
fore being stored at –70°C until required; the RNA was 
spectrophotometrically quantitated (Ultrospec 2100pro, 
Amersham Biosciences, Little Chalfont, England). 
RNA was reverse transcribed into cDNA using an 
oligo-dT primer and M-MLV reverse transcriptase 
(Promega, Madison, WI, USA), in the presence of rR-
Nasin Ribonuclease Inhibitor (Promega). Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH; as house 
keeping gene) and S100B mRNAs were amplified using 
gene-specific primer sets (COSMO Genetech, Seoul, Ko-
rea) (Table 1) and Taq polymerase (Promega) on a Gen-
eAmp PCR System 9600 (Perkin-Elmer Corp., Norwalk, 
CT, USA). The products were subjected to 2% agarose 
gel electrophoresis (Mupid a, Advance, Kasugai, Japan) 
and band density (Fig. 2) measured using a GelDoc 2000 
system (Bio-Rad, Hercules, CA, USA) and Quantity One 
software (Bio-Rad). 
Statistical analysis
The differences in the means between groups were de-
termined using analysis of variance and Student t test. 
The differences of median between groups were deter-
mined by non-parametric test (Kruskal-Wallis test or 
Wilcoxon rank-sum test). In non-parametric tests, sig-
nificance of differences between groups was analyzed by 
the Dunn procedure. Correlation between semi-quanti-
tative S100B mRNA levels and the degree of fibrosis was 
calculated using Spearman correlation coefficient. p val-
ues < 0.05 were considered as statistically significant. By 
the Dunn procedure, p values < 0.01 were considered as 
statistically significant. Analyses were performed using 
the R Statistical Package version 3.1.2, (Institute for Sta-
tistics and Mathematics, Vienna, Austria, www.r-project.
org) and SAS version 9.2 (SAS Institute Inc., Cary, NC, 
USA).  
RESULTS
Patient characteristics
Patient characteristics are summarized in Table 2. Mean 
age was younger in CHB (37.5 years) and older in HCC 
patients (62.4 years, p < 0.0001). Level of alanine ami-
notransferase and aspartate aminotransferase between 
groups was not significantly different. The HAI score 
Normal
GAPDH
S-100
CHB CHC LC HCC
Figure 2. Polymerase chain reaction (PCR) expression of 
S100B mRNA. PCR expression of S100B mRNA was de-
creased in patients with chronic liver diseases. CHB, chron-
ic hepatitis B; CHC, chronic hepatitis C; LC, liver cirrhosis; 
HCC, hepatocellular carcinoma; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase.
Table 1. Primers for S100B and GAPDH 
Transcript Primer pair Sequence Base pair
S100B Forward 5′-ATG TCT GAG CTG GAG AAG G-3′ 338
Reverse 5′-CTG TCT GCT TTC TTG CAT G-3′
GAPDH Forward 5′-TGA TGA CAT CAA GAA GGT GGT GAA G-3′ 240
Reverse 5′-TCC TTG GAG GCC ATG TGG GCC AT-3′
GAPDH, glyceraldehyde 3-phosphate dehydrogenase. 
272 www.kjim.org
The Korean Journal of Internal Medicine Vol. 32, No. 2, March 2017
https://doi.org/10.3904/kjim.2015.296
was significantly highest in LC patients (p = 0.005). Fi-
brosis scores (CHB vs. CHC vs. LC; 1.7 ± 1.1, 1.2 ± 0.8, 3.5 ± 
0.9, p < 0.0001) were significantly highest in LC patients 
(Table 2).The difference in the fibrosis score was not sta-
tistically significant between CHB and CHC patients (p 
= 0.24). 
Hepatic nerve density
In normal controls, S100B-positive nerve fibers were lo-
cated in the portal tracts, and along the sinusoids in the 
hepatic lobules. In CHB and CHC patients, they were 
found in the portal tracts, but were rare in hepatic lob-
ules. In LC patients, nerve fibers were noted in fibrous 
septae, but were rare in regenerating nodules (Fig. 1). 
Table 2. Characteristics of patients
Characteristic
Controls
(n = 3)
CHB
(n = 32)
CHC
(n = 14)
LC
 (n = 14)
HCC
(n = 7)
p value
Age, yr 43.0 ± 7.0 37.5 ± 13.8 49.9 ± 14.0 49.7 ± 8.7 62.4 ± 12.4 < 0.0001
AST, IU/L - 164.2 85.8 167.2 58.3
ALT, IU/L - 253.3 133.1 114.8 30.3
Total bilirubin, mg/dL - 1.0 0.9 1.9 1.1
Direct bilirubin, mg/dL - 0.5 0.4 0.9 0.5
HAI score - 8.21 ± 4.03 6.86 ± 2.32 11.29 ± 3.54 - 0.005a
Fibrosis score - 1.75 ± 1.14 1.21 ± 0.80 3.50 ± 0.85 - < 0.0001b
Median Fibrosis score - 1 1 4 - < 0.0001c
Values are presented as mean ± SD. The fibrosis score were determined in terms of Knodell’s HAI. 
CHB, chronic hepatitis B; CHC, chronic hepatitis C; LC, liver cirrhosis; HCC, hepatocellular carcinoma; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; HAI, histological activity index.
aCHB vs. LC, p = 0.029; CHC vs. LC, p = 0.005. 
bCHB vs. LC, p < 0.0001; CHC vs. LC, p < 0.0001. 
cCHB vs. LC, p = 0.0004; CHC vs. LC, p < 0.0001. 
Table 3. Semi-quantitation of S100B mRNA and hepatic nerve density in the portal tract and hepatic lobule
Variable Control CHB CHC LC HCC p value
Semi-quantitation of S100B mRNA 3 32 14 14 7
S100B 1,689.9 1,427.6 1,463.0 1,623.1 1,438.4
GAPDH 1,413.4 1,534.6 1,681.5 1,766.7 1,672.3
S100B/GAPDH ratio
Mean ± SD 1.21 ± 0.07 0.94 ± 0.12 0.88 ± 0.12 0.93 ± 0.12 0.86 ± 0.09 0.0007
Mean ± SD 0.92 ± 0.12a 0.0002
Median 1. 23 0.93 0.88b 0.92 0.89b 0.023
Median 0.91a, 0.91c < 0.05d
Hepatic nerve density by S100B stain  2 14 12 10 7
Median portal tract 3.42 2.50 1.00 1.75 2.0 0.158e
Median hepatic lobule 1.42 0.50 0.33 0.25f 1.5 0.231e
CHB, chronic hepatitis B; CHC, chronic hepatitis C; LC, liver cirrhosis; HCC, hepatocellular carcinoma; GAPDH, glyceralde-
hyde 3-phosphate dehydrogenase.
aCH, chronic hepatitis (CHB, CHC).
bControl vs. CHC, p = 0.002; Control vs. HCC, p = 0.003. 
cCLD, chronic liver diseases (CHB, CHC, and LC).
dControl vs. CH, p = 0.0008; Control vs. CLD, p = 0.006. 
eThe hepatic nerve density by S100B stain from HCC was excluded.
fControl vs. LC, p = 0.025.
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The hepatic nerve density in the portal tracts and hepat-
ic lobules was decreased in patients with chronic liver 
diseases overall. In the hepatic lobular area, the nerve 
densities of cirrhotic regenerating nodules were signifi-
cantly lower than the lobular nerve densities of control 
patients (p = 0.025) (Table 3). When comparing the hepat-
ic nerve densities of each chronic liver diseases, there 
were no differences in either portal tracts (p = 0.158) or 
hepatic lobules (p = 0.231).
Semi-quantitation of S100B mRNA (S100B/GAPDH 
mRNA ratio)
The S100B/GAPDH mRNA ratio ranged from 0.717 to 
1.27. The S100B/GAPDH mRNA ratio was decreased in 
patients with chronic liver diseases (p = 0.006) (Fig. 3). 
This ratio was significantly decreased in CHC among 
groups (p = 0.023) (Table 3). The S100B/GAPDH mRNA 
ratio was significantly decreased in CHC (vs. control, p 
= 0.002) and in HCC patients (vs. control, p = 0.003). The 
S100B/GAPDH mRNA ratio of chronic hepatitis patients 
overall was lower than that of the control group (1.22 vs. 
0.91, p = 0.006), although CHC patients had a non-sig-
nificantly lower S100B/GAPDH mRNA ratio than CHB 
patients (p = 0.12). In chronic liver disease patients, the 
S100B/GAPDH mRNA ratio tended to decrease as the 
fibrosis score increased, but the trend was not statisti-
cally significant (p = 0.453) (Fig. 4). There was no statisti-
cally significant correlation between the S100B/GAPDH 
mRNA ratio and the fibrosis score (r = 0.061, p = 0.657). 
DISCUSSION
The human liver is innervated by the sympathetic and 
parasympathetic nervous systems [1]. The nerve fibers 
end on hepatocytes that are adjacent to the connective 
tissue of the portal triads [13]. Serial sections have re-
vealed that the nerve fibers arise from nerve bundles in 
the intrahepatic bile ducts [13]. Electron microscopy has 
shown that arterioles and bile ducts are in direct contact 
with these nerve fibers [11]. Liver innervation comprises 
sympathetic, parasympathetic, and peptidergic nerve fi-
bers, organized as either afferent or efferent nerves [14]. 
In human liver, nerve endings in the intralobular spaces 
are located mainly in the Disse spaces and are oriented 
toward the hepatic stellate cells, sinusoidal endothelial 
cells, and hepatocytes [15]. This study evaluated the topo-
graphical changes in the hepatic nerve by investigating 
S100B protein expression using immunohistochemis-
try, and semi-quantitatively by monitoring S100B mRNA 
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Figure 3. S100B/glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA ratio in control and various liver diseases. 
Compared to the control group, the S100B/GAPDH mRNA 
ratio was significantly decreased in chronic liver diseases 
(p = 0.006). Among groups, the S100B/GAPDH mRNA ratio 
was significantly decreased in chronic hepatitis C (CHC) 
patients (p = 0.023). CHB, chronic hepatitis B; LC, liver cir-
rhosis; HCC, hepatocellular carcinoma.
Figure 4. The S100B/glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) mRNA ratio and fibrosis scores in chronic 
liver diseases. In chronic liver diseases, The S100B/GAPDH 
mRNA ratio tended to decrease as the fibrosis score > 0 (p = 
0.453), but the overall correlation between the S100B/GAPDH 
mRNA ratio and fibrosis score was not statistically signifi-
cant (r = 0.061, p = 0.657). r (rho), Spearman correlation coeffi-
cient. 
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expression gauged as the S100B/GAPDH mRNA ratio, in 
chronic liver disease subjects, as compared to subjects 
with normal livers.
Quantification of the hepatic nerve in liver diseases 
has been reported in a few studies, but the results are 
still controversial. The density of the hepatic nerve has 
been measured in previous studies by calculating the 
number of positively stained cells in a microscopic field 
[11,16,17]. Nam et al. [11] reported a decreased density of 
the hepatic nerve in patients with chronic liver diseases, 
and this density was significantly lower in patients with 
LC than in normal controls. Terada and Nakanuma [15] 
reported a higher density of the hepatic nerve in hepa-
tolithiasis and extrahepatic biliary obstruction than in 
normal human livers. Matsunaga et al. [18] reported that 
S100-positive nerve fibers in the stroma were signifi-
cantly denser in patients with chronic liver disease than 
in those with normal livers. The stained nerve fibers 
were manually counted in the above-mentioned stud-
ies, so that errors in quantifying positively stained fibers 
might have affected the results. 
In contrast, Terada and Nakanuma [15] reported that 
nerve fibers were dense in patients with hepatolithiasis, 
intermediate in patients with extrahepatic biliary ob-
struction, and sparse in normal controls. S100-positive 
nerve fibers in the stroma were significantly increased 
in patients with chronic liver diseases compared to 
those with normal livers, and the S100-positive nerve fi-
ber density was significantly higher in patients with all 
types of chronic liver disease than in those with normal 
livers in yet another study [18], and was thought to be 
due to nerve regeneration during chronic liver inflam-
mation [16,18]. The proliferated Schwann cells seemed 
to form a scaffold guiding regenerating nerve fibers [19]. 
Considering that the noradrenergic fibers run along 
blood vessels, changes in vascular patterns may also alter 
hepatic innervation patterns [19,20]. Moreover, scar for-
mation, with changes in the microcirculatory dynamics 
could influence nerve regeneration [20], and changes in 
vascularity and inflammation can affect nerve expres-
sion [19,21].
In our study, LC patients showed decreased hepatic 
nerve density in regenerating nodules compared to that 
of control group (Table 3), in accordance with previous 
studies [2,11,22]. Nam et al. [11] suggested that decreased 
hepatic innervation in LC and chronic hepatitis patients 
might be caused by progressive fibrosis. Nerve fibers 
were also completely absent in patients with advanced 
cirrhosis, suggesting that parenchymal nerves may be 
damaged by progressive fibrosis [22]. The presence of 
regenerating nodules, as an abnormal growth mode, 
may contribute to sinusoidal denervation and structural 
changes may be responsible for the lack of parenchymal 
nerves in cirrhosis and the relative abundance of nerves 
in fibrous septa [22]. 
As hepatic fibrosis occurs in the portal spaces and 
extends into the parenchyma, proliferated capillaries, 
together with fibrous tissues, fibrosis may invade the 
parenchymal remnants from the enlarged portal spaces, 
which may result in structural changes in the lobules 
in chronic liver disease [20] and which suggests that he-
patic parenchymal nerve damage becomes more promi-
nent as fibrosis progresses. 
In our study, S100B mRNA expression was signifi-
cantly lower in chronic liver disease than in the control 
group. However, within the chronic liver diseases group, 
the increase in the fibrosis score failed to show signifi-
cant correlation with S100B mRNA expression. From 
these findings, we cautiously suggest that a decrease of 
S100B expression as a marker of hepatic nerve might 
be an early event of chronic liver diseases and fibrosis 
progression, as an early chronic hepatitis stage prior to 
progression to cirrhosis. Once the chronic liver diseas-
es process is activated, the S100B expression seems not 
to change markedly, as the expression was not differ-
ent among chronic liver diseases and was not correlated 
with fibrosis scores.
Structural changes in the lobules in patients with 
chronic liver diseases may also result in altered nerve 
fiber distribution [2]. Hepatic nerve density in regen-
erating nodules was significantly decreased in patients 
with LC in this study, and Miyazawa et al. [2] have pre-
viously reported that nerve fibers were decreased or al-
together absent in the pseudolobules of cirrhotic liver, 
whereas they were increased markedly in fibrous septae. 
Jaskiewicz et al. [23] also reported that hepatic parenchy-
mal nerves were absent in cirrhotic nodules and were 
depleted in the fibrotic strands of alcoholic cirrhotic 
livers. Using electron microscopy, we evaluated hepat-
ic nerves in one normal control, and in nine CHB, five 
CHC, one LC, and two HCC patients and noted that the 
basement membrane of hepatic nerve ending was dis-
275
Baik SJ, et al. Decreased S100B expression in CLD
www.kjim.orghttps://doi.org/10.3904/kjim.2015.296
rupted in patients with chronic hepatitis (Supplemen-
tary Fig. 1). Another study reported that unmyelinated 
nerve fiber bundles in the intralobular connective tissue 
coursed in the vicinity of hepatic triads [11]. Unmyelin-
ated nerve fibers, including axons, mitochondria, and 
lysosomes were found in the vicinity of portal tract and 
bile duct cells in our specimens.
However, we were not able to correlate these findings 
with hepatic nerve density or S100B expression. Further 
electron microscopic studies are warranted to clarify the 
meaning of these ultrastructural changes in chronic liv-
er diseases. 
There were several limitations to this study. The num-
ber of enrolled patients, and particularly the number of 
control samples was small, and all of them were wom-
en. The mean age of the patients was different between 
groups. The stained nerve fibers were manually count-
ed, which could affect the results. However, our findings 
of decreased hepatic innervation in chronic liver diseas-
es may facilitate understanding of chronic liver disease 
or liver fibrosis.
In conclusion, the S100B/GAPDH mRNA ratio, and 
S100B protein expression, as a marker of hepatic nerves, 
was decreased in patients with chronic liver diseases and 
compared to the normal controls; hepatic nerve density 
was decreased in regenerating nodules in patients with 
LC. Decrease in S100B expression as a marker of hepatic 
nerves might be an early event in chronic liver disease 
progression, representing an early chronic hepatitis 
stage before progression to cirrhosis. Further studies are 
needed to clarify the association between hepatic inner-
vation and structural changes in hepatic lobules.
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Supplementary Figure 1. Electron microscopic findings of 
the hepatic nerve. Disruption of basement membrane in he-
patic nerve ending is indicated as arrows (chronic hepatitis 
B patient, ×50,000). 
